Revolutionary Treatments for Early-Stage Dupuytren’s Disease: A Review

Today, a review providing evidence-based treatments for early stage Dupuytren’s disease has been published in The Journal of Hand Surgery (European Volume) by 180 Life Sciences Corp. This review aims to provide innovative solutions to those suffering from this condition.

In a recent publication, Professors Jagdeep Nanchahal and his colleague from the University of Oxford discuss the lack of evidence-based treatments for early-stage Dupuytren’s disease, such as intranodular injection of steroid or radiotherapy. Through studying cellular signaling mechanisms in tissue from patients, they identified tumor necrosis factor (TNF) as a potential therapeutic target. The phase 2a dose ranging trial identified the most efficacious dose and formulation of adalimumab, followed by a phase 2b trial which met the primary endpoint of reduction in nodule hardness and the secondary endpoint of decrease in nodule size, indicating the potential to control progression of early-stage disease. With these promising results, Professor Nanchahal and his team are hopeful that they can revolutionize the current treatment options for Dupuytren’s disease.

“A breakthrough review of early-stage Dupuytren’s disease treatments, co-authored by Professor Nanchahal and his team at the University of Oxford, has been recently published in a prestigious journal. According to Professor Marc Feldmann FRS, co-chairman of 180 Life Sciences, this review provides a comprehensive summary of the evidence for current treatments for the condition.”

Dr. James Woody, CEO of 180 Life Sciences, is eager to explore the potential of anti-TNF to treat early-stage Dupuytren’s disease. He believes research and clinical findings offer strong support for the use of this treatment, which could benefit countless patients.

About 180 Life Sciences Corp.

180 Life Sciences Corp. is revolutionizing the healthcare industry with its groundbreaking clinical programs and studies. The Company is pioneering a novel treatment for inflammatory disorders by targeting the root cause – TNF (tumor necrosis factor). This approach is designed to address major unmet medical needs and has the potential to transform lives.

Leave a Comment